She grew up in Zimbabwe amidst the infectious disease epidemics of the 80's and 90's. From an early age, she had instilled in her the urgency of disease prevention and cure, as she watched the "six killer diseases" ravage her home country and the rest of the developing world. This first-hand experience showed her the stark linkage between disease management and resource constraints (now a reality for developed and lesser-developed countries) and she decided to spend her life shaping effective solutions to these challenges and fighting for sustainable, accessible healthcare for all countries.

Today, Annastasiah is an experienced strategist, executive, investment professional, and entrepreneur. She has incorporated into Mawambo her expansive knowledge of Nanotechnology, Nanoelectronics, Data as a Centralized Platform, and Artificial Intelligence (AI) with her expertise and network in biomedical discovery, research & technology development, healthcare delivery, and fundraising to further her mission of accelerating global healthcare solutions.

Utilizing her experience in emerging technologies cross-disciplinary and multi-stakeholder approaches, Annastasiah co-founded the Alliance for Artificial Intelligence in Healthcare (AAIH), a global coalition of 30+ organizations dedicated to resolving the myriad challenges facing the growing field of AI- and Machine Learning-based life sciences and healthcare solutions. In addition to her proven track record of over 50+ cross-industry deals in both the private and public sectors, Annastasiah worked for a leading management consultant firm, a global clinical research organization, and co-founded five companies ($70M+ in Series A) within the drug development and nanotechnology sectors. This includes a mid-stage AI-supported nanotechnology platform for diagnostics, disease management, therapeutic monitoring, data processing, and transmission at the point-of-need. Annastasiah also serves as a digital health subject matter expert on National Science Foundation’s (NSF) SBIR/STTR proposal review panels.

Annastasiah holds several advisory roles in academia and industry, including on the Medical and Advisory Council for Global Genes, a rare disease advocacy organization, and serves on the board of the Belgian-American Chamber of Commerce (BelCham), which promotes transatlantic business growth and collaboration. She received her PhD in Cellular and Molecular Medicine from Johns Hopkins Medicine where she developed a clinical phase oncology drug, and obtained her Bachelor of Science in Chemistry [Highest Honors, Summa Cum Laude] from the University of Pittsburgh.